The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
J | Antiinfectives for systemic use | |
2
|
J01 | Antibacterials for systemic use | |
3
|
J01M | Quinolone antibacterials | |
4
|
J01MA | Fluoroquinolones | |
5
|
J01MA14 | Moxifloxacin |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| ORAL | Oral | 0.4 g | |
| PAREN | Parenteral | 0.4 g |
| Active Ingredient |
|---|
|
Moxifloxacin, a fourth-generation fluoroquinolone, has in vitro activity against a wide range of Gram-positive and Gram-negative pathogens. The bactericidal action of moxifloxacin results from the inhibition of both type II topoisomerases (DNA gyrase and topoisomerase IV) required for bacterial DNA replication, transcription and repair. |
| Document | Type | Information Source | |
|---|---|---|---|
| AVELOX Film-coated tablet | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| AVELOX Solution for infusion | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) | |
| ERELAN Film-coated tablet | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.